- Home
- PR vs QGEN Comparison
PR vs QGEN Comparison
Compare PR & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PR
- QGEN
- Stock Information
- Founded
- PR 2015
- QGEN 1986
- Country
- PR United States
- QGEN Netherlands
- Employees
- PR N/A
- QGEN N/A
- Industry
- PR Oil & Gas Production
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PR Energy
- QGEN Health Care
- Exchange
- PR Nasdaq
- QGEN Nasdaq
- Market Cap
- PR 9.6B
- QGEN 9.1B
- IPO Year
- PR 2016
- QGEN 1996
- Fundamental
- Price
- PR $14.17
- QGEN $47.90
- Analyst Decision
- PR Strong Buy
- QGEN Buy
- Analyst Count
- PR 15
- QGEN 8
- Target Price
- PR $18.29
- QGEN $50.68
- AVG Volume (30 Days)
- PR 13.2M
- QGEN 1.3M
- Earning Date
- PR 08-05-2025
- QGEN 08-05-2025
- Dividend Yield
- PR 4.22%
- QGEN 3.16%
- EPS Growth
- PR 39.99
- QGEN N/A
- EPS
- PR 1.62
- QGEN 0.42
- Revenue
- PR $5,134,186,000.00
- QGEN $2,002,874,000.00
- Revenue This Year
- PR $7.10
- QGEN $6.36
- Revenue Next Year
- PR $1.46
- QGEN $6.18
- P/E Ratio
- PR $8.76
- QGEN $113.79
- Revenue Growth
- PR 37.00
- QGEN 3.31
- 52 Week Low
- PR $10.01
- QGEN $37.63
- 52 Week High
- PR $16.95
- QGEN $48.82
- Technical
- Relative Strength Index (RSI)
- PR 54.44
- QGEN 61.89
- Support Level
- PR $13.60
- QGEN $47.25
- Resistance Level
- PR $14.64
- QGEN $48.82
- Average True Range (ATR)
- PR 0.46
- QGEN 0.75
- MACD
- PR -0.04
- QGEN -0.12
- Stochastic Oscillator
- PR 49.68
- QGEN 68.29
About PR Permian Resources Corporation
Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization and development of oil and liquids-rich natural gas assets. The Company's assets and operations are concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).